Industry: Healthcare | Publish Date: 14-Feb-2024 | No of Pages: 101 | No. of Tables: 71 | No. of Figures: 36 | Format: PDF | Report Code : N/A
The France Dialysis Market size was valued at USD 5.35 billion in 2023, and is expected to reach USD 6.71 billion by 2030, with a CAGR of 3.3% from 2024 to 2030.
The dialysis market constitutes a specialized segment within the healthcare sector, dedicated to delivering artificial kidney functions to individuals experiencing impaired renal function. This pivotal medical procedure, known as dialysis, plays a life-sustaining role in the management of patients grappling with end-stage renal disease (ESRD) or acute kidney injuries.
Within this market, a diverse array of products and services is encompassed, spanning hemodialysis and peritoneal dialysis equipment, dialysis consumables, and associated pharmaceuticals. Given the escalating prevalence of kidney-related disorders coupled with the burgeoning aging population, the dialysis market assumes a critical role in providing indispensable renal care. Its primary objective is to elevate the quality of life for patients while concurrently contributing to overall healthcare improvements.
The escalating healthcare expenditure is a pivotal driver for the France dialysis market, fostering increased investments in renal care infrastructure. As countries allocate substantial resources to enhance their healthcare systems, the expansion of dialysis services becomes a focal point.
This augmented financial commitment translates into improved accessibility to dialysis facilities, upgraded medical equipment, and enhanced patient care. The growing healthcare expenditure underscores a collective effort to address the rising prevalence of kidney-related ailments, further propelling the demand for dialysis treatments and positively impacting the overall market dynamics.
The surge in diabetes and hypertension cases in the country contributes significantly to the growth of the market. These chronic conditions, especially when unmanaged, can lead to kidney damage and eventually chronic kidney disease (CKD).
With the increasing prevalence of diabetes and hypertension, there is a corresponding rise in the incidence of CKD, necessitating the use of dialysis as a crucial therapeutic intervention. The expanding patient pool with these comorbidities underscores the importance of dialysis services in managing kidney-related complications, driving the demand for dialysis treatments.
One of the significant challenges in the France dialysis market is the integral risk of infections and difficulties associated with these procedures. Poor adherence to stringent hygiene practices and inadequate sterilization measures can elevate infections, posing a threat to patient health.
Additionally, complications arising from the dialysis process itself can contribute to treatment challenges. Addressing these risks through rigorous quality control measures, training healthcare professionals, and promoting adherence to established protocols is essential to enhance the safety profile of dialysis treatments, fostering better patient outcomes and confidence in the market.
The emergence of wearable and portable dialysis devices stands as a groundbreaking advancement in dialysis technology, offering a transformative opportunity for the dialysis market. These compact systems, resembling small backpacks, empower patients with unprecedented mobility and flexibility in their treatment schedules.
For instance, AWAK Technologies (AWAK), an innovative medical technology firm specializing in dialysis using regenerative technology for end-stage renal disease, revealed that the U.S. Food and Drug Administration (FDA) conferred the breakthrough device designation upon its AWAK Peritoneal Dialysis (AWAK PD) device.
This device, which is both wearable and highly portable, incorporates AWAK's patented sorbent technology. As technology continues to advance, we can anticipate further innovations in dialysis technology, ultimately leading to even better outcomes for patients.
Several market players operating in the France dialysis market include Baxter International, Inc., DaVita Inc., Nikkiso Co. Ltd., NxStage Medical, Inc., Asahi Kasei Corporation, Medicators, Inc, Fresenius Medical Care AG & Co. KGaA, Nipro Corporation, B. Braun Avitum AG, Diaverum Deutschland GmbH, and others.
Hemo Dialysis
Peritoneal Dialysis
Equipment
Consumables
Drugs
Services
In-center Dialysis
Home Dialysis
REPORT SCOPE AND SEGMENTATION:
Parameters |
Details |
Market Size in 2023 |
USD 5.35 Billion |
Revenue Forecast in 2030 |
USD 6.71 Billion |
Growth Rate |
CAGR of 3.3% from 2024 to 2030 |
Analysis Period |
2023–2030 |
Base Year Considered |
2023 |
Forecast Period |
2024–2030 |
Market Size Estimation |
Billion (USD) |
Growth Factors |
|
Companies Profiled |
10 |
Market Share |
Available for 10 companies |
Customization Scope |
Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and Purchase Options |
Avail customized purchase options to meet your exact research needs. |
Baxter International, Inc.
DaVita Inc.
Nikkiso Co. Ltd.
NxStage Medical, Inc.
Asahi Kasei Corporation
Medicators, Inc.
Fresenius Medical Care AG & Co. KGaA
Nipro Corporation
B. Braun Avitum AG
Diaverum Deutschland GmbH